Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Parasitol. 2010 Aug;26(8):395-403. doi: 10.1016/j.pt.2010.04.012. Epub 2010 Jun 9.

Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas.

Author information

1
Molecular Parasitology Unit, Institute of Tropical Medicine, B-2000 Antwerpen, Belgium.

Abstract

The protozoan diseases leishmaniasis, human African trypanosomiasis and Chagas disease are responsible for substantial global morbidity, mortality and economic adversity in tropical and subtropical regions. In most countries, existing strategies for control and treatment are either failing or under serious threat. Environmental changes, drug resistance and immunosuppression contribute to the emergence and spread of these diseases. In the absence of safe and efficient vaccines, chemotherapy, together with vector control, remains the most important measures to control trypanosomatid diseases. Here, we review current limitations of anti-trypanosomatid chemotherapy and describe new efforts to safeguard existing treatments and to identify novel drug leads through the three multinational and interdisciplinary European Union Framework Programmes for Research and Technological Development (FP7) funded consortia KALADRUG-R, TRYPOBASE, and LEISHDRUG.

PMID:
20538522
DOI:
10.1016/j.pt.2010.04.012
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center